DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar Et Al US 20090226,500A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 AVelar et al. (43) Pub. Date: Sep. 10, 2009 (54) SUTURES AND ANTI-SCARRINGAGENTS Related U.S. Application Data (75) Inventors: Rui Avelar, Vancouver (CA); (60) Provisional application No. 60/763.945, filed on Jan. Arpita Maiti, Vancouver (CA); 31, 2006. Philip M. Toleikis, Vancouver (CA); Johanne Diane Cashman, Publication Classification Vancouver (CA); David M. (51) Int. Cl. Gravett, Mountain View, CA (US) A6IF 2/04 (2006.01) Correspondence Address: A63L/35 (2006.01) SEED INTELLECTUAL PROPERTY LAW A 6LX 3/553 (2006.01) GROUP PLLC A63/496 (2006.01) 701 FIFTHAVENUE, SUITE 5400 A63L/464 (2006.01) SEATTLE, WA 98104-7092 (US) A 6LX 3L/395 (2006.01) A6II 3/426 (2006.01) (73) Assignee: Angiotech Pharmaceuticals, Inc. (52) U.S. Cl. .................... 424/423: 514/649; 514/211.08: Vancouver (CA) 514/254.07: 514/399; 514/183: 514/370 (21) Appl. No.: 12/162,572 (57) ABSTRACT (22) PCT Filed: Jan. 31, 2007 Sutures are used in combination with anti-scarring agents to (86). PCT No.: PCT/US07/02714 inhibit fibrosis between the sutures and the host tissues into which the Sutures are inserted. Compositions and methods are S371 (c)(1), described for use in reducing excessive scarring, Surgical (2), (4) Date: May 6, 2009 adhesion, and other disorders. Patent Application Publication Sep. 10, 2009 Sheet 1 of 29 US 2009/0226500 A1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 29 US 2009/0226,500 A1 ºs||eoL-AHLKquoqonpoudp-JNLWu018=ºolZ802-14Ke8 Patent Application Publication Sep. 10, 2009 Sheet 3 of 29 US 2009/0226,500 A1 s LIOC Patent Application Publication Sep. 10, 2009 Sheet 4 of 29 US 2009/0226500 A1 g 9 S Y s s O D. C. war 809 club 9. Patent Application Publication Sep. 10, 2009 Sheet 5 of 29 US 2009/0226500 A1 s E S O 9 was a E s C. Y s del 9 Patent Application Publication Sep. 10, 2009 Sheet 6 of 29 US 2009/0226,500 A1 s to 9, Patent Application Publication Sep. 10, 2009 Sheet 7 of 29 US 2009/0226,500 A1 ' s' t E;E. .." Eigi E s E.3. E.S. E. ESSES SEE seesaaSS eye says 8 E s Patent Application Publication Sep. 10, 2009 Sheet 8 of 29 US 2009/0226,500 A1 al 3.ive s E8 f s Patent Application Publication Sep. 10, 2009 Sheet 9 of 29 US 2009/0226,500 A1 E. E. 5 ., E A eme ve ed R a SS ses e. SS int 3 S 'g a e) ifas as to gi32 (S is on as ae E. A. S. Patent Application Publication Sep. 10, 2009 Sheet 10 of 29 US 2009/0226,500 A1 Patent Application Publication Sep. 10, 2009 Sheet 11 of 29 US 2009/0226,500 A1 i. e. Cld - is 5 apie AP-1 FIG. 10B Patent Application Publication Sep. 10, 2009 Sheet 12 of 29 US 2009/0226500A1 (-01 x udo) 4AHby YO Patent Application Publication Sep. 10, 2009 Sheet 13 of 29 US 2009/0226,500 A1 SIROMELYSIN GAPDH FIG 10D Patent Application Publication Sep. 10, 2009 Sheet 14 of 29 US 2009/0226,500 A1 ly 290 18 SL-1 (ng/ml) .0 20 20 20 20, 20 Drug () 0 0 10 10- 0-5 10 FIG. 1 1A Patent Application Publication Sep. 10, 2009 Sheet 15 of 29 US 2009/0226,500 A1 2-Methyl-2,4-Pentanediol (Hexylene Glycol) collagenase GAPDH IL-1 (ng/ml) 0, 20 20, 20. 20 Drug (M) O. O. 107 10 10 16-4 FIG 11B Patent Application Publication Sep. 10, 2009 Sheet 16 of 29 US 2009/0226,500 A1 Deuterium Oxide 99.9eforn2D Cologenase . :: :-. Patent Application Publication Sep. 10, 2009 Sheet 17 of 29 US 2009/0226,500 A1 Glycine Ethyi Esfer Collagenase . r. isa ist ... " . p . ."s . b Geon his f IL-1 (ng/ml) 0, 20 20 20 20, 20 Drug (M) 0 0 107 10-6 10-5 10 FIG. 1 1D Patent Application Publication Sep. 10, 2009 Sheet 18 of 29 US 2009/0226,500 A1 (succinimidylsuccinole)Ethylene Glycol Bis Collagenase M t frag s . s e. rus s . A A. s i;P. ... v. i; is see : GAPDH o IL-1 (ng/ml). D 20 2020. 20.20 Drug (M) 0 0 10-7 10-6 10-5 10-4 FIG. 11E Patent Application Publication Sep. 10, 2009 Sheet 19 of 29 US 2009/0226,500 A1 Tubercidin l-k (ng/ml), 9, 20 20 20 20 20 Drug (M). O: 0 10-7 10-6 10-5 10 FIG 11 F Patent Application Publication Sep. 10, 2009 Sheet 20 of 29 US 2009/0226,500 A1 Aluminum Fluoride Patent Application Publication Sep. 10, 2009 Sheet 21 of 29 US 2009/0226,500 A1 Epothilone B Collegenase up s GAPDH L-1 (ng/ml) O 20 20 20 Drug (M) 0 0 109 10-7 FIG. 11H Patent Application Publication Sep. 10, 2009 Sheet 22 of 29 US 2009/0226500A1 s g r w . unopells Patent Application Publication Sep. 10, 2009 Sheet 23 of 29 US 2009/0226500 A1 5 S s E 9. () s Locu% Patent Application Publication Sep. 10, 2009 Sheet 24 of 29 US 2009/0226,500 A1 E s E Vs s t s s Ocul Patent Application Publication Sep. 10, 2009 Sheet 25 of 29 US 2009/0226,500 A1 3 E S c o ser 5 s O3 , Patent Application Publication Sep. 10, 2009 Sheet 26 of 29 US 2009/0226,500 A1 or 9. Patent Application Publication Sep. 10, 2009 Sheet 27 of 29 US 2009/0226,500 A1 s O. Patent Application Publication Sep. 10, 2009 Sheet 28 of 29 US 2009/0226,500 A1 o O ar () f Ol - E u) S s edun Na3 Patent Application Publication Sep. 10, 2009 Sheet 29 of 29 US 2009/0226,500 A1 TGF-8 level in Rat Tissues 6 O O O SOOO . 4OOO to implant 3OOO . Shan 2000 1 OOO . O -- -T, a - --fil Shoticer Hip Abdorner Site FIG. 19 US 2009/0226500 A1 Sep. 10, 2009 SUTURES AND ANTI-SCARRINGAGENTS related complications include chronic back or pelvic pain, intestinal obstruction, urethral obstruction and Voiding dys BACKGROUND OF THE INVENTION function. Relieving the post-Surgical complications caused by adhesions generally requires another Surgery. However, 0001 1. Field of the Invention the Subsequent Surgery is further complicated by adhesions 0002 The present invention relates generally to pharma formed as a result of the previous Surgery. In addition, the ceutical agents and compositions for administration in asso second Surgery is likely to result in further adhesions and a ciation with sutures. More specifically, the present invention continuing cycle of additional Surgical complications relates to compositions and methods for preparing Sutures 0007 Adhesions generally begin to form within the first that inhibits a fibrotic response between the sutures and the several days after Surgery Generally, adhesion formation is an tissue in contact with the Suture material. inflammatory reaction in which factors are released, increas 0003 2. Description of the Related Art ing vascular permeability and resulting in fibrinogen influx 0004 Surgical adhesions are abnormal, fibrous bands of and fibrin deposition. This deposition forms a matrix that scar tissue that can form inside the body as a result of the bridges the abutting tissues. Fibroblasts accumulate, attach to healing process that follows any open or minimally invasive the matrix, deposit collagen and induce angiogenesis. If this Surgical procedure including abdominal, gynecologic, car cascade of events can be prevented within 4 to 5 days follow diothoracic, spinal, plastic, vascular, ENT, opthalmologic, ing Surgery, then adhesion formation may be inhibited. urologic, neuro, or orthopedic Surgery. Surgical adhesions are 0008 Various modes of adhesion prevention have been typically connective tissue structures that form between adja examined, including (1) prevention of fibrin deposition, (2) cent injured areas within the body. Briefly, localized areas of reduction of local tissue inflammation and (3) removal of injury trigger an inflammatory and healing response that cul fibrin deposits. Fibrin deposition is prevented through the use minates in healing and scar tissue formation. If scarring of physical barriers that are either mechanical or comprised of results in the formation offibrous tissue bands or adherence of Viscous solutions. Barriers have the added advantage of adjacent anatomical structures (that should be separate), Sur physically preventing adjacent tissues from contacting each gical adhesion formation is said to have occurred. Adhesions can range from flimsy, easily separable structures to dense, other and thereby reducing the probability that they will scar tenacious fibrous structures that can only be separated by together. Although many investigators and commercial prod Surgical dissection. While many adhesions are benign, some ucts utilize adhesion prevention barriers, a number of techni can cause significant clinical problems and are a leading cal difficulties exist and significant failure rates have been cause of repeat surgical intervention. Surgery to breakdown reported. Inflammation is reduced by the administration of adhesions (adhesiolysis) often results in failure and recur drugs such as corticosteroids and non-steroidal anti-inflam rence because the Surgical trauma involved in breaking down matory drugs. However, the results from the use of these the adhesion triggers the entire process to repeat itself. Sur drugs in animal models have not been encouraging due to the gical breakdown of adhesions is a significant clinical problem extent of the inflammatory response and dose restriction due and it is estimated that there were 473,000 adhesiolysis pro to systemic side effects.
Load more

Recommended publications
  • ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
    REVIEW published: 07 October 2020 doi: 10.3389/fimmu.2020.576745 ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19 † † Donato Zipeto 1 , Julys da Fonseca Palmeira 2 , Gustavo A. Argañaraz 2 and Enrique R. Argañaraz 2* 1 Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, 2 Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Bras´ılia, Brasilia, Brazil The Coronavirus Disease 2019 (COVID-19) has already caused hundreds of thousands of deaths worldwide in a few months. Cardiovascular disease, hypertension, diabetes and chronic lung disease have been identified as the main COVID-19 comorbidities. Moreover, Edited by: despite similar infection rates between men and women, the most severe course of the Yolande Richard, Institut National de la Sante´ et de la disease is higher in elderly and co-morbid male patients. Therefore, the occurrence of Recherche Me´ dicale (INSERM), specific comorbidities associated with renin–angiotensin system (RAS) imbalance France mediated by the interaction between angiotensin-converting enzyme 2 (ACE2) and Reviewed by: desintegrin and metalloproteinase domain 17 (ADAM17), along with specific genetic Andreas Ludwig, RWTH Aachen University, factors mainly associated with type II transmembrane serine protease (TMPRSS2) Germany expression, could be decisive for the clinical outcome of COVID-19. Indeed, the Elena Ciaglia, — University of Salerno, Italy exacerbated ADAM17 mediated ACE2, TNF-a, and IL-6R secretion emerges as a Rumi Ueha, possible underlying mechanism for the acute inflammatory immune response and the University of Tokyo, Japan activation of the coagulation cascade. Therefore, in this review, we focus on the main *Correspondence: pathophysiological aspects of ACE2, ADAM17, and TMPRSS2 host proteins in COVID- Enrique R.
    [Show full text]
  • Advanced Glycation End Products Evoke Endothelial Cell Damage By
    Ishibashi et al. Cardiovascular Diabetology 2013, 12:125 CARDIO http://www.cardiab.com/content/12/1/125 VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin- like growth factor II receptor Yuji Ishibashi1, Takanori Matsui1, Sayaka Maeda1, Yuichiro Higashimoto2 and Sho-ichi Yamagishi1* Abstract Background: Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 diabetes. However, the role of DPP-4 in AGE-induced endothelial cell (EC) damage remains unclear. Methods: In this study, we investigated the effects of DPP-4 on reactive oxygen species (ROS) generation and RAGE gene expression in ECs. We further examined whether an inhibitor of DPP-4, linagliptin inhibited AGE-induced soluble DPP-4 production, ROS generation, RAGE, intercellular adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) gene expression in ECs. Results: DPP-4 dose-dependently increased ROS generation and RAGE gene expression in ECs, which were prevented by linagliptin. Mannose 6-phosphate (M6P) and antibodies (Ab) raised against M6P/insulin-like growth factor II receptor (M6P/IGF-IIR) completely blocked the ROS generation in DPP-4-exposed ECs, whereas surface plasmon resonance revealed that DPP-4 bound to M6P/IGF-IIR at the dissociation constant of 3.59 x 10-5 M. AGEs or hydrogen peroxide increased soluble DPP-4 production by ECs, which was prevented by N-acetylcysteine, RAGE-Ab or linagliptin.
    [Show full text]
  • 81969413.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector European Journal of Pharmacology 698 (2013) 74–86 Contents lists available at SciVerse ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Molecular and cellular pharmacology Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats Gisele Giannocco a,b, Kelen C. Oliveira a,b, Renato O. Crajoinas c, Gabriela Venturini c, Thiago A. Salles c, Miriam H. Fonseca-Alaniz c, Rui M.B. Maciel b, Adriana C.C. Girardi c,n a Department of Morphology and Physiology, Faculdade de Medicina do ABC, Santo Andre´,Sao~ Paulo, SP, Brazil b Department of Medicine, Federal University of Sao~ Paulo, Sao~ Paulo, SP, Brazil c University of Sao~ Paulo Medical School, Heart Institute, Laboratory of Genetics and Molecular Cardiology, Avenida Dr. Ene´as de Carvalho Aguiar 44, 101 andar, Bloco II, 05403-900 Sao Paulo, Brazil article info abstract Article history: The purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV (DPPIV) Received 26 January 2012 inhibitor sitagliptin, which exerts anti-hyperglycemic and anti-hypertensive effects, upregulates GLUT4 Received in revised form translocation, protein levels, and/or mRNA expression in heart and skeletal muscle of spontaneously 19 September 2012 hypertensive rats (SHRs). Ten days of treatment with sitagliptin (40 mg/kg twice daily) decreased Accepted 21 September 2012 plasma DPPIV activity in both young (Y, 5-week-old) and adult (A, 20-week-old) SHRs to similar Available online 7 October 2012 extents (85%).
    [Show full text]
  • Structural Basis for the Sheddase Function of Human Meprin Β Metalloproteinase at the Plasma Membrane
    Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane Joan L. Arolasa, Claudia Broderb, Tamara Jeffersonb, Tibisay Guevaraa, Erwin E. Sterchic, Wolfram Boded, Walter Stöckere, Christoph Becker-Paulyb, and F. Xavier Gomis-Rütha,1 aProteolysis Laboratory, Department of Structural Biology, Molecular Biology Institute of Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona Science Park, E-08028 Barcelona, Spain; bInstitute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, D-24118 Kiel, Germany; cInstitute of Biochemistry and Molecular Medicine, University of Berne, CH-3012 Berne, Switzerland; dArbeitsgruppe Proteinaseforschung, Max-Planck-Institute für Biochemie, D-82152 Planegg-Martinsried, Germany; and eInstitute of Zoology, Cell and Matrix Biology, Johannes Gutenberg-University, D-55128 Mainz, Germany Edited by Brian W. Matthews, University of Oregon, Eugene, OR, and approved August 22, 2012 (received for review June 29, 2012) Ectodomain shedding at the cell surface is a major mechanism to proteolysis” step within the membrane (1). This is the case for the regulate the extracellular and circulatory concentration or the processing of Notch ligand Delta1 and of APP, both carried out by activities of signaling proteins at the plasma membrane. Human γ-secretase after action of an α/β-secretase (11), and for signal- meprin β is a 145-kDa disulfide-linked homodimeric multidomain peptide peptidase, which removes remnants of the secretory pro- type-I membrane metallopeptidase that sheds membrane-bound tein translocation from the endoplasmic membrane (13). cytokines and growth factors, thereby contributing to inflammatory Recently, human meprin β (Mβ) was found to specifically pro- diseases, angiogenesis, and tumor progression.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Market Cap Close ADV
    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Ipo Analysis
    IPO ANALYSIS Snap Research on potential upcoming IPOs from Hamilton Lane Bitcoin Investment Trust selected candidate companies. Visterra Braeburn Pharmaceuticals December, 2016 VentureDeal Snap Files S-1 Registration For $3 Billion IPO Quick Take Camera company Snap Inc. (Pending:SNAP) has filed its initial S-1 registration for a $3 billion IPO at an undisclosed valuation. Snap views the camera as the primary use of the mobile device and seeks to monetize its user base primarily through advertising. The company has a short history of rapidly growing revenues, which exceeded $400 million in 2016. Company Venice-based Snap was founded in 2012 by current CEO Evan Spiegel and current CTO Robert Murphy to initially provide users with a smartphone app that enabled them to post pictures that were automatically deleted after a brief time period. The company has since expanded its scope to include chat, video, media that does not become automatically deleted, and a camera integrated into sunglasses. Below is a brief company video on its recently introduced Spectacles product: (Source: Snap YouTube) Snap has raised in excess of $2.6 billion in several private financing rounds from numerous investors including top tier venture capital firms, corporate investors, private equity firms and government-owned investment enterprises. The company claims that 158 million people use its flagship Snapchat each day, creating over 2.5 billion 'Snaps'. Market and Competition Snap operates a largely advertising-driven business model, although it does sell its Spectacles product for $129 each. It seeks to provide advertisers with access to its user base, which has typically centered around a younger demographic, between the ages of 14-30.
    [Show full text]
  • Fidelity® Total Market Index Fund
    Quarterly Holdings Report for Fidelity® Total Market Index Fund May 31, 2021 STI-QTLY-0721 1.816022.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.3% Shares Value Shares Value COMMUNICATION SERVICES – 10.1% World Wrestling Entertainment, Inc. Class A (b) 76,178 $ 4,253,780 Diversified Telecommunication Services – 1.1% Zynga, Inc. (a) 1,573,367 17,055,298 Alaska Communication Systems Group, Inc. 95,774 $ 317,970 1,211,987,366 Anterix, Inc. (a) (b) 16,962 838,941 Interactive Media & Services – 5.6% AT&T, Inc. 11,060,871 325,521,434 Alphabet, Inc.: ATN International, Inc. 17,036 805,292 Class A (a) 466,301 1,099,001,512 Bandwidth, Inc. (a) (b) 34,033 4,025,764 Class C (a) 446,972 1,077,899,796 Cincinnati Bell, Inc. (a) 84,225 1,297,065 ANGI Homeservices, Inc. Class A (a) 120,975 1,715,426 Cogent Communications Group, Inc. (b) 66,520 5,028,912 Autoweb, Inc. (a) (b) 6,653 19,028 Consolidated Communications Holdings, Inc. (a) 110,609 1,035,300 Bumble, Inc. 77,109 3,679,641 Globalstar, Inc. (a) (b) 1,067,098 1,707,357 CarGurus, Inc. Class A (a) 136,717 3,858,154 IDT Corp. Class B (a) (b) 31,682 914,343 Cars.com, Inc. (a) 110,752 1,618,087 Iridium Communications, Inc. (a) 186,035 7,108,397 DHI Group, Inc. (a) (b) 99,689 319,005 Liberty Global PLC: Eventbrite, Inc. (a) 114,588 2,326,136 Class A (a) 196,087 5,355,136 EverQuote, Inc.
    [Show full text]
  • WO 2017/019841 Al 2 February 2017 (02.02.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/019841 Al 2 February 2017 (02.02.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/32 (2006.01) A61L 27/14 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/42 (2006.01) A61L 27/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/0444 11 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 28 July 2016 (28.07.2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/197,693 28 July 2015 (28.07.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: TRUSTEES OF TUFTS COLLEGE TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [US/US]; Ballou Hall, Medford, Massachusetts 02155 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (US).
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]